[August 05, 2004] Research and Markets: Cell Therapy - Technologies, Markets and Companies DUBLIN, Ireland --(Business Wire)-- Aug. 5, 2004 -- The Value for Cell Therapy Technologies is Estimated to Increase to $35.7 Billion by the Year 2007 and $81.3 Billion by the Year 2012 Research and Markets (http://www.researchandmarkets.com) has announced the addition of Cell Therapy - Technologies, Markets and Companies to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of fetal sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices. Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer, which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues. Regulatory and ethical issues involving cell therapy are important and are discussed. Ethical issues concern mainly use of fetal tissues and xenografts from nonhuman primates. Current political debate on the use of stem cells from embryonic sources is also presented. Safety is an essential consideration of any new therapy and regulatory considerations for cell therapy are those for biological preparations. The number of companies involved in cell therapy has increased remarkably during the past few years. More than 200 companies have been identified to be involved in cell therapy and 160 of these are profiled in the report. Important collaborations in the area of cell therapy are shown. Collectively, the value of markets for cell therapy technologies in 2002 was approximately $20.2 billion and is estimated to increase to $35.7 billion by the year 2007 and $81.3 billion by the year 2012. The largest expansion will be in diseases of the central nervous system and cancer. Skin and soft tissue repair as well as diabetes mellitus will be other major markets. Report Contents: Executive Summary 13 1 Introduction to Cell Therapy 17 2 Cell Therapy Technologies 23 3 Stem Cells 43 4 Clinical Applications of Cell Therapy 79 5 Cell Therapy for Cancer 113 6 Cell Therapy for Neurological Disorders 131 7 Ethical, Regulatory, and Safety Aspects of Cell Therapy 165 8 Markets and Future Prospects for Cell Therapy 187 9 Companies Involved in Cell Therapy 195 10 References 363 For more information visit http://www.researchandmarkets.com/reports/c3529 [ Back To TMCnet.com's Homepage ]